Liege, Belgium, 24 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the New Drug Application (NDA) for Estelle® has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021.
Share it
Latest news
Mithra announces updates to its 2024 financial calendar
28 March 2024
Mithra reports full year 2023 financial results
8 March 2024